Results from trial of VGX 3100 vaccine published in The Lancet-Inovio Pharma

The Lancet has published a peer-reviewed article detailing the successful results of a phase IIb trial with VGX 3100 vaccine, from Inovio Pharma, in treating women with high grade cervical neoplasia. Previously, medical researchers have tried to stimulate therapeutic immune responses against the human papillomavirus (HPV) and cervical lesions with little success. This publication details that VGX 3100, a first-in-class product for treating high grade cervical neoplasia associated with HPV, is the first therapy to demonstrate that activated killer T cells induced in the body have the power to clear neoplastic lesions as well as the virus which caused the disease.

See: Safety, efficacy, and immunogenicity of VGX 3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomized, double-blind, placebo-controlled phase 2b trial